You just read:

XARELTO® (rivaroxaban) Significantly Reduced Major Cardiovascular Events in Patients with Stable Coronary and Peripheral Artery Disease in Pivotal Phase 3 Study

News provided by

Janssen

Aug 27, 2017, 05:27 ET